Tag: <span>draws scrutiny</span>

Home / draws scrutiny
Iveric drug approved for type of vision loss as rival’s safety draws scrutiny
Post

Iveric drug approved for type of vision loss as rival’s safety draws scrutiny

Cleared by the FDA to treat geographic atrophy, the drug was a key reason Japan’s Astellas bought Iveric for $5.9 billion in May.Published Aug. 5, 2023 Ben FidlerSenior Editor Associated with age-related macular degeneration, geographic atrophy causes irreversible vision loss. Alexander Ford via Getty Images The Food and Drug Administration on Friday approved a second medicine...